From Proteopedia

proteopedia linkproteopedia link

Revision as of 22:54, 28 January 2020 (edit) Ivan E. Wang (Talk | contribs) ← Previous diff		Revision as of 22:58, 28 January 2020 (edit) (undo) Ivan E. Wang (Talk | contribs) Next diff →
Line 14:		Line 14:
	== Enzymatic Catalyzed Reaction ==		== Enzymatic Catalyzed Reaction ==
	(PLACEHOLDER)		(PLACEHOLDER)
-	[[Image:Visual Cycle.jpg]]	+	[[Image:Visual Cycle.jpg|thumb|left|alt=Figure 2: Human Visual Cycle| Figure 2: The canonical Visual Cycle in Humans <ref>DOI 10.1016/j.bbadis.2018.04.014</ref>]]

---

Revision as of 22:58, 28 January 2020

Retinal Pigment Epithelium 65 (Retinoid Isomerohydrolase) complex with (R/S)-emixustat and palmitate

spinqualitylabelsall models Emixustat bound in the active site of RPE65 Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image Retinal pigment epithelium 65 (RPE65) also known as retinoid isomerohydrolase is a 65 kDa enzyme located within the human retinal pigment epithelium cells responsible for the chemical conversion of all-trans-retinyl ester to 11-cis-retinol in the visual cycle.

(PLACEHOLDER This is a default text for your page Ivan E. Wang/Sandbox 1. Click above on edit this page to modify. Be careful with the < and > signs. You may include any references to papers as in: the use of JSmol in Proteopedia ^[1] or to the article describing Jmol ^[2] to the rescue.)

Contents 1 Function 1.1 Structural Features of RPE65 1.2 Enzymatic Catalyzed Reaction 2 Protein-Ligand Interaction 2.1 Endogenous Ligand 2.2 Exogenous Ligand 2.3 R/S Enantiomers Differences 3 Disease Implications 4 Medical Relevance 5 References

Function

Structural Features of RPE65

(PLACEHOLDER)

Enzymatic Catalyzed Reaction

(PLACEHOLDER)

Protein-Ligand Interaction

Endogenous Ligand

(PLACEHOLDER)

Exogenous Ligand

spinqualitylabelsall models PDB ID 4ryy Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image (R)-Emixustat (ACU-4429) (R)-emixustat (ACU-4429) is an investigational small molecule inhibitor of RPE65 first invented by a British-American chemist, Ian L. Scott. Formulated as an hydrochloride salt, (R)-emixustat hydrochloride is taken by mouth and functions as a visual cycle modulator (VCM) to reduce toxic retinal byproducts such as A2E. In 2008, Acucela Inc. partnered with Otsuka Pharmaceutical Company for the continued development of (R)-emixustat as a potential inhibitor of RPE65. Currently (R)-emixustat is in Phase III clinical trials in the United States for the potential treatment of Stargard's disease, a juvenile form of atrophic (dry) age dependent macular degeneration (AMD). Additionally, (R)-emixustat is investigated as potential therapy for diabetic retinopathy and diabetic macular edema.

spinqualitylabelsall models PDB ID 4ryz Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image (S)-Emixustat (PLACEHOLDER)

R/S Enantiomers Differences

(PLACEHOLDER)

Disease Implications

(PLACEHOLDER)

Medical Relevance

(PLACEHOLDER)

This is a sample scene created with SAT to by Group, and another to make of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.

References

1. ↑ Hanson, R. M., Prilusky, J., Renjian, Z., Nakane, T. and Sussman, J. L. (2013), JSmol and the Next-Generation Web-Based Representation of 3D Molecular Structure as Applied to Proteopedia. Isr. J. Chem., 53:207-216. doi:http://dx.doi.org/10.1002/ijch.201300024
2. ↑ Herraez A. Biomolecules in the computer: Jmol to the rescue. Biochem Mol Biol Educ. 2006 Jul;34(4):255-61. doi: 10.1002/bmb.2006.494034042644. PMID:21638687 doi:10.1002/bmb.2006.494034042644
3. ↑ Shin Y, Moiseyev G, Petrukhin K, Cioffi CL, Muthuraman P, Takahashi Y, Ma JX. A novel RPE65 inhibitor CU239 suppresses visual cycle and prevents retinal degeneration. Biochim Biophys Acta Mol Basis Dis. 2018 Jul;1864(7):2420-2429. doi:, 10.1016/j.bbadis.2018.04.014. Epub 2018 Apr 21. PMID:29684583 doi:http://dx.doi.org/10.1016/j.bbadis.2018.04.014